Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School. To read the full story.
Home / News / Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
Recent Posts
- NIH Fellowship Writing Group: Call for Applications – Sign Up by 8/25
- Rutgers Students Showcase AI-Driven Research Success Through NJ ACTS Summer Research Program
- Rutgers NJHealth Study Data Access Opportunity – Application Due July 6th!
- Rutgers researchers: How Meta turned teen attention into a public health crisis.
- Kids under 5 are grabbing their parents’ vapes and getting sick at record levels, researchers say.
Categories
- Community (2,498)
- Covid (1,001)
- CTO Events (6)
- News (3,172)
- Pilots (21)